Merck launched its new Cellstream benchtop flow cytometry system — a compact, customizable flow cytometer that uses a camera for detection. According to the manufacturer, its unique optics system and design provide researchers with unparalleled sensitivity and flexibility when analyzing cells and submicron particles.
Darmstadt/Germany — Merck developed this new technology with the same patent-protected optics system as its Amnis flow cytometers, which are used in academic, biotech and pharmaceutical cell analysis and research applications. The system’s Amnis time-delay integration and camera technology rapidly captures low-resolution cell images and converts them to high-throughput intensity data with enhanced fluorescence sensitivity. It can be used in a wide variety of research areas, including exosome research, where it can identify small populations unable to be seen on other cytometers. The new system expands the company’s portfolio of flow cytometry platforms.
Jean-Charles Wirth, head of the Applied Solutions business unit, Life Science, at Merck, commented that Cellstream expands the limits of sensitivity, allowing scientists to tailor their instrument to their needs in immunology, cancer research and many other areas.
Cellstream features a fully customizable 7-laser capacity that provides unparalleled versatility and the capability to obtain up to 22 detection channels. With its patent-protected TDI sensor and camera technology the system enables high fluorescence sensitivity. The system may be fully and quickly upgraded on-site to add more lasers if needed. A standard 96-well plate auto-sampler is available on all instruments to capture high-throughput intensity data. Finally, its event gallery allows visual verification of cell populations and helps troubleshoot.
